In the year 1960 the active ingredient Delta-9-tetrahydrocannabinol (THC) was firstly extracted by an Israelian scientist. Ablin (2016) connects the finding to the Cannabis friendly and liberal legislation in Israel. Back than most other countries strictly regulated the research on Cannabis.
The medical use of Cannabis is primarily attributed to the two dominant Cannabinoids THC and the CBD (Cannabidiol).
Both substances are successfully used in the medical treatment of symptoms such as
nausea, vomiting, muscle twitching, spasm, pain and inflammation. Disorders such as multiple sclerosis, epilepsy, HIV, nociception, glaucoma, insomnia and asthma.
(Albin 2016, Small 2015).
In recent years, psychotic side effects have been described by patients while consuming isolated or synthetic THC. This could be underlined in several clinical studies.
These side effects were significantly reduced by the addition of CBD (Schubart 2011) or by the intake of raw plant material.
The exact relationship between therapeutic use and the composition of secondary ingredients has not been investigated so far.
Small (2015) has shown in his review that the therapeutic benefit seems to be a combination of different ingredients. These include not only the over 100 cannabinoids, but also terpene and flavonoids.
A long-term study in the Netherlands has shown that fromm 200-2005 the THC content in cannabis products offered at coffee shops increased substantially. Since 2005, the THC content is slowly decreasing and the ratio between CBD / THC appears to become more important for the consumers.
The liberalization of the use of Cannabis in many countries around the globe leads to a increasing information exchange. There is an increasing number in academic and clinical research and people are getting more interested in Cannabis not only being a psychoactive drug, but seeing the great medicinal potential.